Pfizer's experimental drug slows incurable breast cancer, findings show


Pfizer's experimental breast cancer drug stopped progression of an incurable form of the disease for more than two years in a study, a dramatic delay for those with the second deadliest cancer in women.

Patients were given the medicine, called PD 0332991, along with Novartis's Femara. The findings, reported Wednesday at the San Antonio Breast Cancer Symposium in Texas, showed no tumor progression for a median of 26.1 months, compared with 7.5 months in those who received Femara alone. Results were from the second of three stages of testing normally needed for U.S. approval.

The medicine is the first in a new class of agents that works by blocking a protein critical in the cancer cell cycle, said lead researcher Richard Finn. It's also among the most promising in New York-based Pfizer's drug development pipeline, with the potential for generating $5 billion in annual sales for breast and other tumor types, Andrew Baum, an analyst at Citigroup in London, wrote in a note to investors.

"This magnitude of benefit is probably one of the largest with any new agent in breast cancer, or perhaps any solid tumor," Finn, an associate professor of medicine at the Jonsson Comprehensive Cancer Center at the University of California, Los Angeles, said in a telephone interview. "It's dramatic to see this level of benefit with a new agent."

The findings are noteworthy because of the size of the benefit and comparative safety of the experimental treatment, said Claudine Isaacs, an oncologist and professor of medicine at Georgetown Lombardi Comprehensive Cancer Center in Washington. The study, involving 165 patients with metastatic disease, was small and must be confirmed in larger trials, she said.

The study included women with tumors fueled by the hormone estrogen, the most common type of breast cancer. All had metastatic disease, which had spread to other parts of the body and is no longer considered curable.

Breast cancer is the most common tumor in women. Almost 230,000 women in the United States will be diagnosed with it this year, and more than 39,900 will die from it, according to the American Cancer Society. Lung cancer is the deadliest form of the disease for women.

"It does make you stop and look," Isaacs said in a telephone interview. The results are "much more marked than we typically see. It's hard to ignore that," she said. "It's not something that is changing practice today, but it's definitely something to keep one's eye on."

Investors have overlooked the drug's "mega-blockbuster potential," said Baum, the Citigroup analyst. Pfizer is at least two years ahead of its closest competitors, Eli Lilly & Co. and Novartis, with similar cancer drugs in development, he said in his Nov. 29 investment note.


Pfizer rose 1.9 percent to $25.64 at 4 p.m. New York time. The shares have gained 29 percent in the past 12 months. Onyx Pharmaceuticals Inc., which licensed rights to the experimental drug to Pfizer, rose 3.4 percent to $77.05.


The results presented Wednesday stem from an interim review of the data and come on top of potent treatment, Finn said.

Forty-five percent of patients given the drug combination responded to therapy, compared with 31 percent given Femara alone. When the researchers included women who had stable disease for six months or more, 70 percent given both drugs benefited, compared with 44 percent of those given Femara.

Pfizer is moving the compound into the final stage of testing needed for approval as quickly as possible, with an international trial in the same type of cancer slated to begin next year, said Mace Rothenberg, senior vice president of clinical development in the company's oncology unit. Additional research is examining other types of tumors, he said.

The company is also talking to regulators to determine what kind of information will be needed to win marketing approval of the medicine, he said in a telephone interview. While the Food and Drug Administration typically requires two studies confirming the benefits of an investigational agent, it has leeway to expedite the process for promising drugs.

About one in three patients needed to have their dose of the experimental drug lowered during the study. Side effects included low levels of infection-fighting white blood cells, anemia and fatigue, though there weren't any serious cases of fever tied to the low white blood cells.

The first 66 patients were post-menopausal women with estrogen-receptor positive cancer. The second 99 patients also had tumors that were fueled by estrogen, though they had genetic alterations the researchers hoped could further identify people who would benefit from the therapy.

About half the women were initially diagnosed with advanced disease and hadn't gotten previous drug treatment. The other half had previously received chemotherapy or treatment after surgery to remove the tumor, Finn said. Laboratory work conducted before the study began suggested the Pfizer medicine was particularly potent against estrogen-receptor positive cancers.

There were no differences in response among women with the biomarkers and those who didn't have them, Finn said. Both sets of patients had a significant benefit.

"The drug obviously hits a critical pathway in estrogen- receptor positive breast cancer," he said. "If we took triple negative breast cancer, we wouldn't expect this result."

Pfizer is reaching out to cancer experts to help devise the most efficient studies to answer questions about when and how the drug should be given, and what other medicines should be given with it to maximize the benefit, Rothenberg said.

"It's an irony of having a drug moving forward as quickly as we can," Rothenberg said. "There will be gaps in our knowledge of how to give it and when. We're trying to move forward with a thoughtful, methodical approach."

The study targeted women who were newly diagnosed with metastatic, or spreading, breast cancer. There are several other effective treatments available even after the experimental compound stops working, Finn said.

"The magnitude of this benefit I don't think should be underestimated," Finn said. "These are patients who have incurable breast cancer. A lot of drugs in oncology have been approved or are getting a lot of traction because of improvements that last weeks to a few months. We have gone from 7 months to 26 months. That's groundbreaking."

Start your day with The Independent, sign up for daily news emails
Life and Style
Steve Shaw shows Kate how to get wet behind the ears and how to align her neck
healthSteven Shaw - the 'Buddha of Breaststroke' - applies Alexander Technique to the watery sport
footballShirt then goes on sale on Gumtree
Terry Sue-Patt as Benny in the BBC children’s soap ‘Grange Hill’
voicesGrace Dent on Grange Hill and Terry Sue-Patt
Arts and Entertainment
Performers drink tea at the Glastonbury festival in 2010
Have you tried new the Independent Digital Edition apps?
ebookA unique anthology of reporting and analysis of a crucial period of history
A poster by Durham Constabulary
Cameron Jerome
footballCanaries beat Boro to gain promotion to the Premier League
Arts and Entertainment
Emily McDowell Card that reads:
artCancer survivor Emily McDowell kicks back at the clichés
Arts and Entertainment
Twin Peaks stars Joan Chen, Michael Ontkean, Kyle Maclachlan and Piper Laurie
tvBadalamenti on board for third series
Life and Style
Standing room only: the terraces at Villa Park in 1935
Ben Stokes celebrates with his team mates after bowling Brendon McCullum
sportEngland vs New Zealand report
Amal Clooney has joined the legal team defending 'The Hooden Men'
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs General

Guru Careers: Software Developer / C# Developer

£40-50K: Guru Careers: We are seeking an experienced Software / C# Developer w...

Guru Careers: Software Developer

£35 - 40k + Benefits: Guru Careers: We are seeking a Software Developer (JavaS...

SThree: Trainee Recruitment Consultant / Resourcer

£18000 - £23000 per annum + Commission: SThree: As a Trainee Recruitment Consu...

Ashdown Group: UI Developer - (UI, HTML, CSS, JavaScript, AngularJS)

£25000 - £40000 per annum: Ashdown Group: UI Developer - (UI, JavaScript, HTML...

Day In a Page

Abuse - and the hell that came afterwards

Abuse - and the hell that follows

James Rhodes on the extraordinary legal battle to publish his memoir
Why we need a 'tranquility map' of England, according to campaigners

It's oh so quiet!

The case for a 'tranquility map' of England
'Timeless fashion': It may be a paradox, but the industry loves it

'Timeless fashion'

It may be a paradox, but the industry loves it
If the West needs a bridge to the 'moderates' inside Isis, maybe we could have done with Osama bin Laden staying alive after all

Could have done with Osama bin Laden staying alive?

Robert Fisk on the Fountainheads of World Evil in 2011 - and 2015
New exhibition celebrates the evolution of swimwear

Evolution of swimwear

From bathing dresses in the twenties to modern bikinis
Sun, sex and an anthropological study: One British academic's summer of hell in Magaluf

Sun, sex and an anthropological study

One academic’s summer of hell in Magaluf
From Shakespeare to Rising Damp... to Vicious

Frances de la Tour's 50-year triumph

'Rising Damp' brought De la Tour such recognition that she could be forgiven if she'd never been able to move on. But at 70, she continues to flourish - and to beguile
'That Whitsun, I was late getting away...'

Ian McMillan on the Whitsun Weddings

This weekend is Whitsun, and while the festival may no longer resonate, Larkin's best-loved poem, lives on - along with the train journey at the heart of it
Kathryn Williams explores the works and influences of Sylvia Plath in a new light

Songs from the bell jar

Kathryn Williams explores the works and influences of Sylvia Plath
How one man's day in high heels showed him that Cannes must change its 'no flats' policy

One man's day in high heels

...showed him that Cannes must change its 'flats' policy
Is a quiet crusade to reform executive pay bearing fruit?

Is a quiet crusade to reform executive pay bearing fruit?

Dominic Rossi of Fidelity says his pressure on business to control rewards is working. But why aren’t other fund managers helping?
The King David Hotel gives precious work to Palestinians - unless peace talks are on

King David Hotel: Palestinians not included

The King David is special to Jerusalem. Nick Kochan checked in and discovered it has some special arrangements, too
More people moving from Australia to New Zealand than in the other direction for first time in 24 years

End of the Aussie brain drain

More people moving from Australia to New Zealand than in the other direction for first time in 24 years
Meditation is touted as a cure for mental instability but can it actually be bad for you?

Can meditation be bad for you?

Researching a mass murder, Dr Miguel Farias discovered that, far from bringing inner peace, meditation can leave devotees in pieces
Eurovision 2015: Australians will be cheering on their first-ever entrant this Saturday

Australia's first-ever Eurovision entrant

Australia, a nation of kitsch-worshippers, has always loved the Eurovision Song Contest. Maggie Alderson says it'll fit in fine